This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morrell, N. W. Articles by Weir, E. K. Search for Related Content PubMed PubMed Citation Articles by Morrell, N. W. Articles by Weir, E. K.

STATE-OF-THE-ART PAPER

Cellular and Molecular Basis of Pulmonary Arterial Hypertension

Nicholas W. Morrell, MA, MD^_*,_*, Serge Adnot, MD, PhD, Stephen L. Archer, MD, Jocelyn Dupuis, MD, PhD, Peter Lloyd Jones, PhD^||, Margaret R. MacLean, PhD^¶, Ivan F. McMurtry, PhD^#, Kurt R. Stenmark, MD^_**, Patricia A. Thistlethwaite, MD, PhD, Norbert Weissmann, PhD, Jason X.-J. Yuan, MD, PhD and E. Kenneth Weir, MD^||||

^_* Pulmonary Vascular Diseases Unit, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
Medical School of Créteil, Hôpital Henri Mondor, Créteil, France
University of Chicago, Chicago, Illinois
Research Center of the Montreal Heart Institute, Department of Medicine, University of Montreal, Montreal, Québec, Canada
^|| University of Pennsylvania, Penn/CMREF Center for Pulmonary Arterial Hypertension Research, Philadelphia, Pennsylvania
^¶ Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland
^# Departments of Pharmacology and Medicine and Center for Lung Biology, University of South Alabama, Mobile, Alabama
^_** Developmental Lung Biology Laboratory and Pediatric Critical Care Medicine, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
Department of Cardiothoracic Surgery, University of California, San Diego, La Jolla, California
University of Giessen Lung Center, Department of Internal Medicine II/V, Justus-Liebig-University, Giessen, Germany
Department of Medicine, University of California San Diego, La Jolla, California
^|||| University of Minnesota, Veterans Affairs Medical Center, Minneapolis, Minnesota

Manuscript received February 6, 2009; accepted April 15, 2009.

^_* Reprint requests and correspondence: Dr. Nicholas W. Morrell, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom (Email: nwm23{at}cam.ac.uk).

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of pulmonary vascular remodeling is accompanied by endothelial dysfunction, activation of fibroblasts and smooth muscle cells, crosstalk between cells within the vascular wall, and recruitment of circulating progenitor cells. Recent findings have reestablished the role of chronic vasoconstriction in the remodeling process. Although the pathology of PAH in the lung is well known, this article is concerned with the cellular and molecular processes involved. In particular, we focus on the role of the Rho family guanosine triphosphatases in endothelial function and vasoconstriction. The crosstalk between endothelium and vascular smooth muscle is explored in the context of mutations in the bone morphogenetic protein type II receptor, alterations in angiopoietin-1/TIE2 signaling, and the serotonin pathway. We also review the role of voltage-gated K⁺ channels and transient receptor potential channels in the regulation of cytosolic [Ca²⁺] and [K⁺], vasoconstriction, proliferation, and cell survival. We highlight the importance of the extracellular matrix as an active regulator of cell behavior and phenotype and evaluate the contribution of the glycoprotein tenascin-c as a key mediator of smooth muscle cell growth and survival. Finally, we discuss the origins of a cell type critical to the process of pulmonary vascular remodeling, the myofibroblast, and review the evidence supporting a contribution for the involvement of endothelial-mesenchymal transition and recruitment of circulating mesenchymal progenitor cells.

Key Words: pulmonary arterial hypertension • cellular • molecular basis

Abbreviations and Acronyms   ALK = activin-receptorlike kinase   Ang = angiopoeitin   BMP = bone morphogenetic protein   BMPR = bone morphogenetic protein receptor   cGMP = cyclic guanosine monophosphate   EC = endothelial cell   ECM = extracellular matrix   enMT = endothelial mesenchymal transition   eNOS = endothelial nitric oxide synthase   GTPase = guanosine triphosphatase   5-HT = hydroxytryptamine (serotonin)   5-HTT = hydroxytryptamine (serotonin) transporter   IPAH = idiopathic pulmonary arterial hypertension   MLC = myosin light chain   MLCK = myosin light chain kinase   MLCP = myosin light chain phosphatase   NO = nitric oxide   PA = pulmonary artery   PAEC = pulmonary artery endothelial cell   PAH = pulmonary arterial hypertension   PAI = plasminogen-activator inhibitor   PAK = p21-activated kinase   PASMC = pulmonary artery smooth muscle cell   PGI2 = prostacyclin   PH = pulmonary hypertension   PK = protein kinase   ROCK = Rho kinase   SMC = smooth muscle cell   TGF = transforming growth factor   TRPC = canonical transient receptor potential

This article has been cited by other articles:

				E. M. Abud, J. Maylor, C. Undem, A. Punjabi, A. L. Zaiman, A. C. Myers, J. T. Sylvester, G. L. Semenza, and L. A. Shimoda Digoxin inhibits development of hypoxic pulmonary hypertension in mice PNAS, January 24, 2012; 109(4): 1239 - 1244. [Abstract] [Full Text] [PDF]

				M. E. Yeager, C. M. Nguyen, D. D. Belchenko, K. L. Colvin, S. Takatsuki, D. D. Ivy, and K. R. Stenmark Circulating fibrocytes are increased in children and young adults with pulmonary hypertension Eur. Respir. J., January 1, 2012; 39(1): 104 - 111. [Abstract] [Full Text] [PDF]

				G. Ghobadi, B. Bartelds, S. J. van der Veen, M. G. Dickinson, S. Brandenburg, R. M. F. Berger, J. A. Langendijk, R. P. Coppes, and P. van Luijk Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension Thorax, December 26, 2011; (2011) thoraxjnl-2011-200346v1. [Abstract] [Full Text]

				R. A. McDonald, A. Hata, M. R. MacLean, N. W. Morrell, and A. H. Baker MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling Cardiovasc Res, December 11, 2011; (2011) cvr299v2. [Abstract] [Full Text] [PDF]

				V. Shlyonsky, I. Ben Soussia, R. Naeije, and F. Mies Opposing Effects of Bone Morphogenetic Protein-2 and Endothelin-1 on Lung Fibroblast Chloride Currents Am. J. Respir. Cell Mol. Biol., December 1, 2011; 45(6): 1154 - 1160. [Abstract] [Full Text] [PDF]

				M. Weng, D. M. Baron, K. D. Bloch, A. D. Luster, J. J. Lee, and B. D. Medoff Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, December 1, 2011; 301(6): L927 - L936. [Abstract] [Full Text] [PDF]

				L. Ikonomou, A. R. Hemnes, G. Bilousova, R. Hamid, J. E. Loyd, A. K. Hatzopoulos, D. N. Kotton, S. M. Majka, and E. D. Austin Programmatic change: lung disease research in the era of induced pluripotency Am J Physiol Lung Cell Mol Physiol, December 1, 2011; 301(6): L830 - L835. [Abstract] [Full Text] [PDF]

				M. Jerkic, M. G. Kabir, A. Davies, L. X. Yu, B. A. S. McIntyre, N. W. Husain, M. Enomoto, V. Sotov, M. Husain, M. Henkelman, et al. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress Cardiovasc Res, December 1, 2011; 92(3): 375 - 384. [Abstract] [Full Text] [PDF]

				L. Zhao, C.-N. Chen, Z. Zhai, and M. R. Wilkins Chapter 2 Pathobiology of pulmonary arterial hypertension OCL Pulmonary Hypertension, December 1, 2011; 1(1): med-9780199572632-chapter - med-9780199572632-chapter. [Abstract] [Full Text]

				N. Weissmann VEGF Receptor Inhibition As a Model of Pulmonary Hypertension in Mice Am. J. Respir. Crit. Care Med., November 15, 2011; 184(10): 1103 - 1105. [Full Text] [PDF]

				L. Ciuclan, O. Bonneau, M. Hussey, N. Duggan, A. M. Holmes, R. Good, R. Stringer, P. Jones, N. W. Morrell, G. Jarai, et al. A Novel Murine Model of Severe Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., November 15, 2011; 184(10): 1171 - 1182. [Abstract] [Full Text] [PDF]

				G. Bussone, M. C. Tamby, C. Calzas, N. Kherbeck, Y. Sahbatou, C. Sanson, K. Ghazal, H. Dib, B. B. Weksler, C. Broussard, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction Ann Rheum Dis, November 14, 2011; (2011) annrheumdis-2011-200195v1. [Abstract] [Full Text]

				E. M. T. Lau, A. Manes, D. S. Celermajer, and N. Galie Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward Eur. Heart J., October 2, 2011; 32(20): 2489 - 2498. [Abstract] [Full Text] [PDF]

				M. Li, S. R. Riddle, M. G. Frid, K. C. El Kasmi, T. A. McKinsey, R. J. Sokol, D. Strassheim, B. Meyrick, M. E. Yeager, A. R. Flockton, et al. Emergence of Fibroblasts with a Proinflammatory Epigenetically Altered Phenotype in Severe Hypoxic Pulmonary Hypertension J. Immunol., September 1, 2011; 187(5): 2711 - 2722. [Abstract] [Full Text] [PDF]

				L. Tu, L. Dewachter, B. Gore, E. Fadel, P. Dartevelle, G. Simonneau, M. Humbert, S. Eddahibi, and C. Guignabert Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension Am. J. Respir. Cell Mol. Biol., August 1, 2011; 45(2): 311 - 322. [Abstract] [Full Text] [PDF]

				M. Weng, M. J. Raher, P. Leyton, T. P. Combs, P. E. Scherer, K. D. Bloch, and B. D. Medoff Adiponectin Decreases Pulmonary Arterial Remodeling in Murine Models of Pulmonary Hypertension Am. J. Respir. Cell Mol. Biol., August 1, 2011; 45(2): 340 - 347. [Abstract] [Full Text] [PDF]

				D. Xu, H. Guo, X. Xu, Z. Lu, J. Fassett, X. Hu, Y. Xu, Q. Tang, D. Hu, A. Somani, et al. Exacerbated Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Animals With Loss of Function of Extracellular Superoxide Dismutase Hypertension, August 1, 2011; 58(2): 303 - 309. [Abstract] [Full Text] [PDF]

				J.-P. Stasch, P. Pacher, and O. V. Evgenov Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease Circulation, May 24, 2011; 123(20): 2263 - 2273. [Full Text] [PDF]

				V. Solodushko, D. F. Alvarez, R. Viator, T. Messerall, and B. Fouty Heterogeneous activation of p19Arf in pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, April 1, 2011; 300(4): L642 - L647. [Abstract] [Full Text] [PDF]

				M. Gomberg-Maitland, C. Dufton, R. J. Oudiz, and R. L. Benza Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?: A Clinical Perspective J. Am. Coll. Cardiol., March 1, 2011; 57(9): 1053 - 1061. [Abstract] [Full Text] [PDF]

				L. Pandit, D. L. Bonilla, and N. T. Eissa Autophagy: A New Frontier in Research in Lung Diseases Am. J. Respir. Crit. Care Med., March 1, 2011; 183(5): 566 - 568. [Full Text] [PDF]

				M. Esfandiarei, J. T. N. Lam, S. A. Yazdi, A. Kariminia, J. N. Dorado, B. Kuzeljevic, H. T. Syyong, K. Hu, and C. van Breemen Diosgenin Modulates Vascular Smooth Muscle Cell Function by Regulating Cell Viability, Migration, and Calcium Homeostasis J. Pharmacol. Exp. Ther., March 1, 2011; 336(3): 925 - 939. [Abstract] [Full Text] [PDF]

				S.-J. Lee, A. Smith, L. Guo, T.-P. Alastalo, M. Li, H. Sawada, X. Liu, Z.-H. Chen, E. Ifedigbo, Y. Jin, et al. Autophagic Protein LC3B Confers Resistance against Hypoxia-induced Pulmonary Hypertension Am. J. Respir. Crit. Care Med., March 1, 2011; 183(5): 649 - 658. [Abstract] [Full Text] [PDF]

				V. J. Burton, L. I. Ciuclan, A. M. Holmes, D. M. Rodman, C. Walker, and D. C. Budd Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function Blood, January 6, 2011; 117(1): 333 - 341. [Abstract] [Full Text] [PDF]

				K. R. Stenmark, M. G. Frid, and M. E. Yeager Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Eur. Respir. J., December 1, 2010; 36(6): 1232 - 1235. [Full Text] [PDF]

				C. Jardim, S. Hoette, and R. Souza Contemporary issues in pulmonary hypertension Eur. Respir. Rev., December 1, 2010; 19(118): 266 - 271. [Full Text] [PDF]

				D. M. Smadja, L. Mauge, O. Sanchez, J.-S. Silvestre, C. Guerin, A. Godier, P. Henno, P. Gaussem, and D. Israel-Biet Distinct patterns of circulating endothelial cells in pulmonary hypertension Eur. Respir. J., December 1, 2010; 36(6): 1284 - 1293. [Abstract] [Full Text] [PDF]

				V. B. Abdul-Salam, J. Wharton, J. Cupitt, M. Berryman, R. J. Edwards, and M. R. Wilkins Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension Circulation, November 16, 2010; 122(20): 2058 - 2067. [Abstract] [Full Text] [PDF]

				E. D. Austin, R. Hamid, and F. Ahmad Somatic Mutations in Pulmonary Arterial Hypertension: Primary or Secondary Events? Am. J. Respir. Crit. Care Med., November 1, 2010; 182(9): 1094 - 1096. [Full Text] [PDF]

				H. A. Ghofrani, N. W. Morrell, M. M. Hoeper, H. Olschewski, A. J. Peacock, R. J. Barst, S. Shapiro, H. Golpon, M. Toshner, F. Grimminger, et al. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy Am. J. Respir. Crit. Care Med., November 1, 2010; 182(9): 1171 - 1177. [Abstract] [Full Text] [PDF]

				B. Rondelet, L. Dewachter, F. Kerbaul, C. Dewachter, I. Hubloue, P. Fesler, S. Franck, M. Remmelink, S. Brimioulle, and R. Naeije Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension Am J Physiol Heart Circ Physiol, October 1, 2010; 299(4): H1118 - H1123. [Abstract] [Full Text] [PDF]

				P. Kumpers, N. Nickel, A. Lukasz, H. Golpon, V. Westerkamp, K. M. Olsson, D. Jonigk, L. Maegel, C. L. Bockmeyer, S. David, et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension Eur. Heart J., September 2, 2010; 31(18): 2291 - 2300. [Abstract] [Full Text] [PDF]

				N. Galie, M. Palazzini, and A. Manes Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses Eur. Heart J., September 1, 2010; 31(17): 2080 - 2086. [Full Text] [PDF]

				D. Montani, L. Savale, D. Natali, X. Jais, P. Herve, G. Garcia, M. Humbert, G. Simonneau, and O. Sitbon Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension Eur. Heart J., August 1, 2010; 31(15): 1898 - 1907. [Abstract] [Full Text] [PDF]

				R. L. Sutliff, B.-Y. Kang, and C. M. Hart PPAR{gamma} as a potential therapeutic target in pulmonary hypertension Therapeutic Advances in Respiratory Disease, June 1, 2010; 4(3): 143 - 160. [Abstract] [PDF]

				M. Toshner, T. Tajsic, and N. W. Morrell Pulmonary hypertension: advances in pathogenesis and treatment Br. Med. Bull., June 1, 2010; 94(1): 21 - 32. [Abstract] [Full Text] [PDF]

				C. G. Elliott, R. J. Barst, W. Seeger, M. Porres-Aguilar, L. M. Brown, R. T. Zamanian, and L. J. Rubin Worldwide Physician Education and Training in Pulmonary Hypertension: Pulmonary Vascular Disease: The Global Perspective Chest, June 1, 2010; 137(6_suppl): 85S - 94S. [Abstract] [Full Text] [PDF]

				G. Hansmann and R. T. Zamanian PPAR{gamma} Activation: A Potential Treatment For Pulmonary Hypertension Science Translational Medicine, December 23, 2009; 1(12): 12ps14 - 12ps14. [Full Text] [PDF]

				The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension Eur. Respir. J., December 1, 2009; 34(6): 1219 - 1263. [Full Text] [PDF]

				M. G. Frid, M. Li, M. Gnanasekharan, D. L. Burke, M. Fragoso, D. Strassheim, J. L. Sylman, and K. R. Stenmark Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1059 - L1072. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]